Pharnext’s Pivotal Phase 3-proef PLEO-CMT wordt belicht tijdens de 22e editie van de Francophone Peripheral Nerve Society Conference
Pharnext’s Pivotal Phase 3-proef PLEO-CMT wordt belicht tijdens de 22e editie van de Francophone Peripheral Nerve Society Conference
PARIJS – (BUSINESS WIRE) – Regulatory News:
Pharnext SA (Parijs: ALPHA) (FR0011191287 – ALPHA), een biofarmaceutisch bedrijf dat baanbrekend werk verricht met een nieuwe aanpak voor de ontwikkeling van innovatieve geneesmiddelen op basis van de combinatie en herpositionering van bekende geneesmiddelen, heeft vandaag aangekondigd dat het bedrijf een update zal presenteren van de lopende cruciale fase 3 Klinische studie PLEO-CMT evalueert PXT3003 voor de behandeling van de ziekte van Charcot-Marie-Tooth type 1A (CMT1A). Dat gebeurt in een mondelinge sessie tijdens de 22e editie van de conferentie van de Francophone Peripheral Nerve Society. De bijeenkomst vindt plaats op 26-27 januari 2018 in Parijs (Frankrijk).
Pharnext’s Pivotal Phase 3 Trial PLEO-CMT to Be Featured at the 22nd Edition of the Francophone Peripheral Nerve Society Conference
PARIS–(BUSINESS WIRE)– Regulatory News:
Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).
Details of the presentation are as follows:
|
Date |
Time |
Session |
||
|
Friday |
From 3:03 |
Selected Oral Communications Session
|
For more information about the event please visit : www.journeessfnp.fr/programme
About Pharnext
Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287).
For more information, visit www.pharnext.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180118005972/en/
Contacts
Pharnext
René Goedkoop,+33 (0)1 41 09 22 30
Chief Medical Officer
medical@pharnext.com
or
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
anne.hennecke@mc-services.eu
or
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
matthew@sternir.com
or
Financial Communication (France)
Actifin
Stéphane Ruiz, +33 (0)1 56 88 11 15
sruiz@actifin.fr
or
Media Relations (Europe)
ALIZE RP
Caroline Carmagnol
Aurore Gangloff
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (U.S.)
RooneyPartners
Marion Janic, +1 212 223 4017
mjanic@rooneyco.com